Associations of fibrinogen and C-reactive protein with prevalent and incident coronary heart disease are attenuated by adjustment for confounding factors

Summary

A cross sectional and prospective analysis of 3,745 British women aged 60–79 years at baseline was undertaken. Among these women there were 570 prevalent cases of coronary heart disease (CHD) and 151 new cases among 12,641 person-years of follow up of women who were free of CHD at baseline. Both fibrinogen and CRP were associated with indicators of socioeconomic position in childhood and adulthood and there was a cumulative effect of socioeconomic position from across the life course. The age-adjusted odds ratio (95% confidence interval) of prevalent CHD for a 1 unit (1 g/L) increase in fibrinogen was 1.29 (1.12, 1.49); with full adjustment for all potential confounding factors this attenuated to 1.09 (0.93, 1.28). The hazards ratio for incident CHD among those free of disease at baseline was 1.28 (1.00, 1.64); with full adjustment for all potential confounding factors this attenuated to 1.09 (0.84, 1.44). Similar effects of adjustment for confounding factors were seen for the associations between CRP and both prevalent and incident CHD. By contrast, the strong positive association between smoking (an established causal risk factor for CHD) and CHD was not attenuated by adjustment for life course socioeconomic position or other risk factors. We conclude that fibrinogen and CRP predict CHD but may not be causally related to it.

Keywords

Fibrinogen / fibrin - atherosclerosis - inflammatory mediators - epidemiology

• References

• 1 Van der Bom JG, De Maat MPM, Bots ML. et al. Elevated plasma fibrinogen. Cause or consequence of cardiovascular disease?Arterioscler Thromb Vasc Biol 1998; 18: 621-5.
• 2 Davey Smith G, Ebrahim S. “Mendelian randomisation“: can genetic epidemiology contribute to understanding environmental determinants of disease?. Int J Epidemiol 2003; 32: 1-22.
• 3 Danesh J, Collins R, Appleby P. et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA 1998; 279: 1477-82.
• 4 Danesh J, Wheeler JG, Hirschfield GH. et al. C-Reactive protein and other circulatingmarkers of inflammation in the prediction of coronary heart disease. New Engl J Med 2004; 350: 1387-97.
• 5 Danesh J, Whincup P, Walker M. et al. Low-grade inflammation and coronary heart disease: prospective study and updated meta-analysis. BMJ 2000; 321: 199-204.
• 6 Lee AJ, Smith WCS, Lowe GDO. et al. Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study. J Clin Epidemiol 1990; 43: 913-9.
• 7 Folsom AR. Epidemiology of fibrinogen. Europ Heart J 1995; 16 (suppl A) 21-4.
• 8 Woodward M, Rumley A, Lowe GDO. et al. C-reactive protein: associations with haematological variables, cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 2003; 121: 135-41.
• 9 Brunner E, Davey Smith G, Marmot M. et al. Childhood social circumstances and psychosocial and behavioural factors as determinants of plasma fibrinogen. Lancet 1996; 347: 1008-13.
• 10 Jousilahti P, Salomaa V, Rasi V. et al. Association of markers of systemic inflammation, C-reactive protein, serum amyloid A, and fibrinogen, with socioeconomic status. J Epidemiol Community Health 2003; 57: 730-3.
• 11 Lowe GDO, Rumley A, Norrie J. et al. on behalf of the West of Scotland Coronary Prevention Group. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study. Thromb Haemost 2000; 84: 553-8.
• 12 Ridker PM, Cushman M, Stampfer MJ. et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New Engl J Med 1997; 336: 973-9.
• 13 Koenig W, Sund M, Frohlich M. et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.
• 14 Benderly M, Graff E, Reicher-Reiss H. et al. Fibrinogen is a predictor of mortality in coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study Group. Arterioscler Thromb Vasc Biol 1996; 16: 351-6.
• 15 Davey Smith G, Hart C, Blane D. et al. Adverse socioeconomic conditions in childhood and cause specific adult mortality: prospective observational study. BMJ 1998; 316: 1631-5.
• 16 Lawlor DA, Davey Smith G, Ebrahim S. The association of childhood socioeconomic position with coronary heart disease risk in post-menopausal women: findings from the British Women's Heart and Health Study. Am J Public Health 2004; 94: 1386-92.
• 17 Galobardes B, Lynch JW, Davey Smith G. Childhood socioeconomic circumstances and cause-specific mortality in adulthood: systematic reviewand interpretation. Epidemiol Rev 2004; 26: 7-21.
• 18 Davey Smith G. Reflections on the limitations to epidemiology. J Clin Epidemiol 2001; 54: 325-31.
• 19 Lawlor DA, Ben-Shlomo Y, Leon DA. Pre-adult influences on cardiovascular disease. Kuh D, Ben-Shlomo Y. eds A life course approach to chronic disease epidemiology 2^ndEdition Oxford: Oxford University Press; 2004
• 20 Lawlor DA, Bedford C, Taylor M. et al. Geographic variation in cardiovascular disease, risk factors and their control in older women: British Women's Heart and Health Study. J Epidemiol Community Health 2003; 57: 134-40.
• 21 Lawlor DA, Ebrahim S, Davey Smith G. Socioeconomic position in childhood and adulthood and insulin resistance: cross sectional survey using data from the British women's heart and health study. Br Med J 2002; 325: 805-7.
• 22 Wannamethee SG, Lowe GDO, Whincup P. et al. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 2002; 105: 1785-90.
• 23 Hernan MA, Hernandez-Diaz S, Werler MM. et al. Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol 2002; 155: 176-84.
• 24 Greenland S, Brumback B. An overview of relations among causal modelling methods. Int J Epid 2002; 31: 1030-7.
• 25 Greenland S. Causal analyses in the health sciences. J Am Statist Assoc 2000; 95: 647-51.
• 26 Lawlor D, Davey Smith G, Ebrahim S. Socioeconomic position and hormone replacement therapy use: explaining the discrepancy in evidence from observational and randomized controlled trials. Am J Public Health 2004; 94: 2149-54.
• 27 Lawlor DA, Ebrahim S, Davey Smith G. Association of self-reported childhood socio-economic position with adult lung function: findings from the British Women's Heart and Health Study. Thorax 2004; 59: 199-203.
• 28 Gunnell D. Can adult anthropometry be used as a 'biomarker' for prenatal and childhood exposures?. Int J Epidemiol 2002; 31: 390-4.
• 29 Emberson JR, Whincup PH, Morris RW. et al. Extent of regression dilution for establishedand novel coronary risk factors: results from the British Regional Heart Study. Eur J Cardiovasc Prevention Rehab 2004; 11: 125-34.
• 30 Phillips AN, Davey Smith G. Bias in relative odds estimation owing to imprecise measurement of correlated exposures. Stat Med 1992; 11: 953-61.
• 31 Margaglione M, Cappucci G, Colaizzo D. et al. Fibrinogen plasma levels in an apparently healthy general population--relation to environmental and genetic determinants. Thromb Haemost 1998; 80: 805-10.
• 32 Fredrikson GN, Hedblad B, Nilsson JA. et al. Association between diet, lifestyle, metabolic cardiovascular risk factors and plasma C-reactive protein levels. Metabolism 2004; 53: 1436-42.
• 33 Davey Smith G, Harbord R, Ebrahim S. Fibrinogen, C-reactive protein and coronary heart disease: does Mendelian randomization suggest the associations are non-causal?. QJM 2004; 97: 163-6.
• 34 Schultz DR, Arnold I P. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. Semin Arthritis Rheum 1990; 20: 129-47.
• 35 Phillips AN, Davey Smith G.. Howindependent are 'independent' effects? Relative risk estimation when correlated exposures aremeasured imprecisely. JClinical Epidemiology 1991; 44: 1223-31.
• 36 Kamath S, Lip GTH. Fibrinogen: biochemisty, epidemiology and determinants. QJM 2003; 96: 711-29.
• 37 Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM 2003; 96: 793-807.
• 38 Writing committee for the Women's Health Initiative randomized controlled trial. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
• 39 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33.
• 40 Meade T, Zuhrie R, Cook C. et al. on behalf of the MRC General Practice Research Framework. Bezafibrate inmen with lower extremity arterial disease: randomised controlledtrial. Br Med J 2002; 325: 1139-43.
• 41 MacCallum P, Cooper JA, Rumley A. et al. Effect of bezafibrate on plasma homocysteine concentration in men with lower extremity arterial disease. J Thromb Haemost 2004; 2: 364-5.
• 42 Fibrinogen Studies Collaboration. Collaborative meta-analysis of prospective observational studies of plasma fibrinogen and cardiovascular disease. Europ J Cardiovasc Prevention Rehab 2004; 11: 9-17.